Previous studies suggested that T-type Ca 2+ -current (I CaT )-blockers improve cardiac remodelling, but all available I CaT -blockers have non-specific actions on other currents and/or functions. To clarify the role of I CaT in cardiac remodelling, we studied mice with either of the principal cardiac I CaT -subunits (Cav3.1 or Cav3.2) knocked out.
Introduction
There are two principle types of Ca 2+ -channels in the heart, 'longlasting' L-type channels, and 'transient' T-type channels. 1,2 L-type Ca 2+ -current (I CaL ) has well-understood roles in cardiac impulse initiation and propagation, arrhythmogenesis, and contraction. The function of T-type Ca 2+ -current (I CaT ) is less well understood.
T-type channels clearly participate in sinus-node pacemaker function and in atrioventricular-node conduction. 3 In addition, there is evidence for a deleterious role of I CaT in cardiac remodelling and arrhythmogenesis. 1 I CaT is strongly expressed in foetal hearts and its expression is greatly reduced in the mature heart; however, cardiac hypertrophy restores I CaT expression to substantial levels. 4 Neonatal cardiomyocyte hypertrophy is induced by hyperglycaemia, concomitant with enhanced I CaT expression. 5 Suppression of I CaT with mibefradil or nickel prevents cell proliferation changes. 5 The I CaT -selective blocker mibefradil improves myocardial remodelling in a variety of paradigms. Mibefradil has been reported to suppress remodelling and improve haemodynamic function in a rat myocardial infarction (MI) model, 6 prevent exercise-induced myocardial stunning in dogs with partial coronary-artery occlusions, 7 and abolish atrial tachycardia-induced arrhythmogenic remodelling in dogs. 8 Comparative studies have shown greater efficacy of mibefradil vs. I CaL -selective inhibitors in post-MI functional and Ca 2+ -handling preservation, 9 in preventing myocardial damage following acute ischaemia and reperfusion in isolated hearts from normal rats 10 and from guinea pigs with acute renal failure, 11 and in preventing arrhythmogenic remodelling by chronic atrial tachycardia in dogs. 12 On the other hand, possible deleterious effects of mibefradil have been reported in post-MI remodelling 13 and on contractile function in hypertrophied hearts. 14 A recent study suggested that the I CaTblockers efonidipine and mibefradil prevent sudden death in mice with heart failure, whereas the I CaL -blocker nitrendipine does not. 15 A major difficulty in establishing the functional role of T-type Ca 2+ channels has been the limited selectivity of pharmacological probes.
1,2
The establishment of the molecular identity of I CaT a-subunits has permitted the development of genetically engineered mice, allowing for clarification of the functional role of I CaT . Mice with increased I CaT due to Cav3.1-subunit overexpression have smaller increases in contractility and no enhanced sarcoplasmic reticulum (SR) Ca
2+
load compared with mice with increased I CaL due to overexpression of the L-type channel b-subunit. 16 Nakayama et al. 17 have shown that Cav3.1 overexpression abrogates, whereas Cav3.1 knockout enhances, overload-, isoproterenol-, and exercise-induced cardiac hypertrophy by a nitric-oxide synthase-dependent mechanism. However, other workers demonstrated that pressure-overload hypertrophy is suppressed in Cav3.2-knockout mice (KO) and unaffected by Cav3.1 deletion. 18 Therefore, the role of I CaT and of its respective subunits in adverse cardiac remodelling remains unclear.
In the present study, we addressed this issue by assessing the effects of Cav3.1 and Cav3.2 knockout in mice subjected to acute MI, a highly clinically relevant form of cardiac remodelling. 
Electrocardiogram and telemetry recording
At baseline and 4 weeks post-MI, mice were anaesthetized for ECG recording with 2.5% isoflurane. Body temperature was maintained at 378C with a heating pad (Harvard Apparatus, USA). A surface ECG (lead I) was obtained with three 25-gauge subcutaneous electrodes and transmitted to a computer via an analogue-digital converter (IOX v1.585, EMKA Technologies) for monitoring and later analysis with ECG-Auto 1.5.12.10 software (EMKA Technologies). Recordings were filtered between 0.5 and 500 Hz. Measurements were based on averages of 10 consecutive complexes. Standard criteria were used to measure RR, PR, QRS, and QT intervals. 19 The QT interval was corrected for heart rate (HR) as follows: corrected QT interval (QTc) ¼ QT/(RR/100) 1/2 , with QT and RR, expressed in milliseconds (ms). 20 To obtain 24 h ECG recordings after LAD ligation in free-moving mice, mice were anaesthetized 1 week before LAD ligation with 2.5% isoflurane delivered via a ventilator. An abdominal incision was made 1.5 cm lateral to the midline to insert a telemetric transmitter (TA10EA-F20, Data Sciences International) into a subcutaneous pocket with paired wire electrodes placed over the thorax (to obtain a bipolar chest ECG lead). Mice were housed in individual cages with free access to food and water and were exposed to 12 h light/dark cycles (light, 6:00 AM to 6:00 PM) in a thermostatically controlled room. ECG signals were computer recorded with the use of a telemetry receiver (RPC1, DSI International), and IOX 2.3 and ECG-Auto 2.4.0.30 (EMKA) systems were used for display and analysis. HR values were determined from average RR intervals over 10 s.
Intra-cardiac recording and pacing
At baseline and 4 weeks after LAD ligation, mice were anaesthetized with 2.5% isoflurane. An octapolar electrophysiology catheter (1.2F) designed for mouse electrophysiology (Biosense Inc.) was positioned in the right ventricle via the right internal jugular vein. Intra-cardiac electrograms were used as a guide for catheter positioning. Surface ECG (lead I) and intra-cardiac electrograms were recorded on a computer through an analogue-digital converter (IOX 1.11, EMKA) for monitoring and later analysis (ECG-Auto 2.1.4.15). Intra-cardiac electrograms were filtered between 0.5 and 500 Hz. Pacing was performed with a custom-built computer-based stimulator triggering a stimulus isolator (509 Stimulator, Grass Telefactor). Standard pacing protocols were used to determine electrophysiological parameters as described elsewhere.
3 Refractory
T-type calcium current and post-MI remodelling periods were determined with a nine-stimulus drive train (S1) at a cycle length of 100 ms followed by a 1.5 × threshold-current premature stimulus (S2) progressively decremented in 2 ms intervals. Atrial, atrioventricular nodal, and ventricular effective refractory periods (AERP, AVERP, and VERP, respectively) were defined as the longest S1-S2 coupling interval that failed to generate a propagated beat. Programmed single, double, and triple extrastimuli were applied at a 100 ms drive cycle length. Burst pacing consisted of trains of 50 paced beats at a cycle length from 50 to 15 ms, with at least a 4 s interval between two successive trains (unless arrhythmias were induced). Ventricular tachycardia (VT) was defined as 10 or more successive spontaneous ventricular beats. Atrial fibrillation (AF) was defined as a rapid and irregular atrial rhythm with variable ventricular response, and was considered sustained if it lasted .1 s before termination.
Echocardiography
Transthoracic echocardiography was performed under 2.5% isoflurane anaesthesia before LAD ligation at baseline, and 4 weeks following MI, using an i13L (10 -14 MHz) probe and a Vivid-7 Dimension system (GE Healthcare Ultrasound, Horten, Norway). The left ventricular (LV) parasternal long-axis view was used to measure the dimension (D) of the LV outflow tract (LVOT). LVOT cross-sectional area (CSALVOT) was calculated as
The LV short-axis view at the papillary muscle level was recorded: LV areas at both cardiac end-diastole (EDA) and end-systole (ESA) were measured with the papillary muscle excluded, along with the LV anterior wall and posterior wall thickness at enddiastole. LV fractional area change was calculated as [(EDA2ESA)/ EDA] × 100%. LV M-mode images at this level were used to determine LV dimensions at end-diastole (LVDd) and end-systole (LVDs). LV fractional shortening (FS) was calculated as [(LVDd2LVDs)/LVDd] × 100%. The Teichholz method was employed to calculate LV volumes and LV ejection fraction (EF). An apical five-chamber view was used to obtain the velocity-time integral of trans-LVOT flow (VTILVOT) with a pulsedwave Doppler proximal to the aortic valve. HR was determined on a simultaneously recorded ECG. Stroke volume (SV) was calculated as SV ¼ VTILVOT × CSALVOT, and cardiac output was calculated as CO ¼ HR × SV. The average of three consecutive cardiac cycles was used for each measurement. Special care was taken to obtain similar imaging planes at baseline and follow-up studies. The operator was blinded to genotype.
Haemodynamic indices
Haemodynamic indices were obtained following catheterization under 2.5% isoflurane anaesthesia. Body temperature was maintained at 378C. A micro-tip Millar-type pressure-volume 1.2F catheter (Scisense Inc., Canada) was inserted into the right carotid artery and advanced into the LV. Correction of the conductance was performed by injecting 5 mL of 20% NaCl into the left jugular vein. At baseline and 4 weeks post-MI, the mean blood pressure, the maximal (+dP/dt) and minimal (2dP/dt) first derivatives of LV pressure, the contractility index, and the relaxation time were calculated with IOX v1.8.9.4 software (EMKA). After the haemodynamic measurements, mice were euthanized by cervical dislocation under 2.5% isoflurane anaesthesia, and the heart was removed and washed in Ca 2+ -free Tyrode solution. The transmural-MI scar was removed and weighed.
Taqman real-time quantitative PCR
The left atrium (LA) and LV were flash-frozen in liquid-N 2 for subsequent RNA isolation. Procedures for the Taqman real-time quantitative polymerase chain reaction (qPCR) followed previously described methods. 21 Total RNA was isolated using the Trizol method (Invitrogen). Total RNA was then treated with DNase I (Sigma Chemicals) to prevent genomic DNA contamination. Lack of genomic DNA contamination was confirmed by PCR. The quality of RNA was assessed with a bioanalyzer (Agilent 2100). Total RNA was reverse-transcribed with the high-capacity reverse transcription kit (Applied Biosystems). qPCR was performed with TaqMan probes and primers from Applied Biosystems on the T-type calcium channel genes: Cav3.1 (Assay ID: Mm00486549_m1), Cav3.2 (Assay ID: Mm00445369_m1). The geometric mean of HPRT1 (Assay ID: Mm00446968_m1) and GAPDH (Assay ID: Mm99999915_g1) was used for normalization. qPCR reactions were performed with the Taqman Gene Expression Master Mix kit (Applied Biosystems). Reactions were run on a Stratagene MX3000. Standard curves were generated for each set of primers over a 2-log range and the efficiencies were 100 + 5%. Relative gene-expression values were calculated by the 2 2DCt method. 21 
Data analysis
Data are expressed as mean + SEM. Unpaired t-tests were used to compare single non-repeated means from different groups and for multiple measures, ANOVA followed by Bonferroni-corrected t-tests or Tukey tests. Fisher's exact test was used to analyse categorical variables.
A two-tailed P-value of ,0.05 denoted statistically significant differences.
Results
Detailed results in both groups for ECG, electrophysiological, echocardiographic, haemodynamic, and heart-weight analyses in all mice at baseline and 4 weeks post-MI are tabulated in Supplementary material online, Tables S1 and S2. Results of particular relevance are presented in figures and described below.
Electrocardiographic recordings, hypertrophic, and infarct-size indices
Examples of typical ECG recordings are shown in Figures 1A-D , and mean data in Figure 1E -H. RR ( Figure 1E ) and PR ( Figure 1F ) intervals were significantly increased in Cav3.1 2/2 mice compared with Cav3.1 +/+ , both at baseline and 4 weeks post-MI, consistent with previous observations. 3 Cav3.1 +/+ and Cav3.1 2/2 mice showed no significant differences in the QRS interval ( Figure 1G ) or QTc ( Figure 1H ), P-wave duration (see Supplementary material online, Table S1 ), or QTc interval ( Figure 1D The ratio of total ventricular weight (TVW) over body weight (BW), an index of cardiac hypertrophy, was increased in both groups 4 weeks post-MI (Figure 2A) , without intergroup differences. Similarly, cell capacitance increased post-MI (see Supplementary material online, Figure S1 ), reflecting cellular hypertrophy, but Cav3. Figure 2C) ; however, no significant difference was observed between the two groups. The infarct size was not different between Cav3.2 +/+ and Cav3.2 2/2 mice ( Figure 2D ).
Cardiac contractility and haemodynamics
LV FS ( Figure 3A) and EF ( Figure 3B) Figure 3C ), but there were no significant differences in the mean blood pressure ( Figure 3D ). There were no significant differences in LV FS ( Figure 3E ), EF ( Figure 3F ), contractility index ( Figure 3G ), or blood pressure ( Figure 3H) Table S2 ).
Cardiac electrophysiology and arrhythmias
Spontaneous ventricular tachyarrhythmias (VTs) were sometimes seen in the first 24 h post-MI ( Figure 4A ). During the 24 h post-MI telemetry period, spontaneous VT occurred in 2 of 7 Cav3.1 +/+ mice and 2 of 6 Cav3.1 2/2 mice ( Figure 5A , P ¼ NS). VTs were also inducible in some mice during electrophysiological study ( Figure 4B ), both at baseline assessment and 4 weeks post-MI. The prevalence of reproducible VT induction ( Figure 5B ) was not significantly different at baseline, occurring Table S1 ), indicating that their longer PR interval was due to abnormal atrioventricular (AV)-node function. Significant differences were also observed in the corrected sinoatrial (SA)-node recovery time at baseline and Wenckebach cycle length at baseline and 4 weeks post-MI (see Supplementary material online, 
Discussion
In this study, we examined the response of Cav3.1 2/2 and Cav3.2
2/2
mice to post-MI remodelling. We found that, contrary to expectations based on most previous pharmacological studies with I CaT -blockers, post-MI remodelling was not improved by I CaT -subunit deletion. In the case of Cav3.1, post-MI remodelling was worsened, and in the case of Cav3.2 it was unaltered.
Comparison with previous studies of effects of I CaT inhibition on cardiac remodelling
A variety of studies used the I CaT -selective blocker mibefradil to assess effects of I CaT inhibition on remodelling. Min et al. 9 observed improved haemodynamics in post-MI rats treated with mibefradil, compared with minor effects of amlodipine and verapamil. Sandmann et al. 6 noted reduced post-MI fibrosis as well as improved haemodynamics with mibefradil, with the greatest benefit observed when treatment began pre-infarction. Mozaffari et al. 22 found that mibefradil was particularly effective in attenuating the effect of high after load on infarct size. Two studies indicated greater protection by mibefradil vs. I CaL -selective . A train of nine basic (S1) stimuli was applied at a 100 ms cycle length, followed by two extrastimuli (S2 and S3).
T-type calcium current and post-MI remodelling blockers against ischaemic damage in Langendorff-perfused hearts. 10, 11 Mibefradil was also found to prevent exercise-induced myocardial stunning in dogs, 7 glucose-induced neonatal-rat cardiomyocyte proliferation, 5 and atrial tachycardia-induced atrial electrical remodelling.
12
Not all studies have pointed to benefits from I CaT -blockade. Xia et al. 13 noted that ramipril improved post-MI remodelling in strokeprone spontaneously hypertensive rats, but that mibefradil was not protective and even increased LV end-diastolic pressures. Takebayashi et al. 14 found deleterious effects on right-ventricular twitch tension in rats exposed to monocrotaline to induce pulmonary hypertension and right-ventricular hypertrophy.
In the present study, we used a genetic-engineering approach to suppress I CaT by specifically knocking out the T-type Ca 2+ -channel subunits Cav3.1 and Cav3.2. We saw no evidence of protection against post-MI remodelling with I CaT a-subunit deletion. On the contrary, Cav3.1-KO mice developed greater post-MI impairments in myocardial function and more arrhythmia susceptibility than WT mice. The discrepancy from previous results obtained with mibefradil as a pharmacological probe may relate to the limited specificity of mibefradil. In addition to inhibiting I CaT , mibefradil also suppresses I CaL , 23 I Na , 24 I Kr , 25 and cytochrome function, 26 any of which could have contributed, along with presently unrecognized actions of the compound, to its effects.
Recent insights into T-type Ca 21 -channel function from genetically engineered mouse models
The ability to produce mice that are genetically engineered to lack Cav3-channel subunits is providing new insights into the functional role of I CaT . Mangoni et al. 3 showed that I Ca knockout impairs sinusnode automaticity and atrioventricular-node conduction, indicating an important role in nodal function. Jaleel et al. 16 not observe an effect of Cav3.1 knockout on pressure-overload hypertrophy, but identified an important role for Cav3.2-subunits in the hypertrophic response to pressure overload, with the presence of Cav3.2-subunits being essential for calcineurin/nuclear factor of activated T-cells hypertrophic signalling to occur. Consistent with the findings of Nakayama et al., and different from those of Chiang et al., we found that Cav3.1 knockout enhanced adverse cardiac remodelling, whereas Cav3.2 knockout had no effect.
Novelty and potential significance
Our study is the first to test the effects of specific T-type I Ca suppression by genetic engineering on the remodelling response to acute MI. We found that, contrary to expectations from most previous pharmacological studies, I CaT suppression is not beneficial against post-MI remodelling, and may in fact be harmful. Adverse myocardial remodelling is an important determinant of outcome after acute MI. 27 There is presently great interest in developing novel therapeutic targets for post-MI remodelling intervention. 28 Based on the available pharmacological data, I CaT appears to be an interesting target. The prototype agent mibefradil was withdrawn because of off-target inhibitory effects on cytochromes that caused potentially disastrous pharmacokinetically based drug interactions. 29 The pharmaceutical industry has been working actively to develop novel T-type Ca 2+ -channel blockers with improved selectivity and safety. One of these, efonidipine, has slightly more T/L-channel-blocking selectivity than mibefradil and has also been shown to have beneficial effects on myocardial remodelling. 30 Our results suggest that I CaT -blockade that targets Cav3.1-subunits may not be a beneficial property and should perhaps be avoided in the search for increasingly selective compounds. Whether targeting other I CaT -subunits like Cav3.2 is beneficial for other forms of remodelling, such as that caused by AF, 8, 12 remains to be determined.
Our work complements recent studies of I CaT participation in hypertrophic mouse models. 17, 18 These studies obtained contradictory information about the role of Cav3.1-subunits. Our observations support the notion that the absence of Cav3.1-subunits exaggerates adverse cardiac remodelling, and argue against negative consequences of Cav3.2 knockout. Our work extends the available knowledge base to the clinically important context of post-MI remodelling, about which there had been no information from mouse models engineered to lack I CaT -subunits. Interestingly, we did not observe any differences in ventricular weight or ventricular weight/BW ratios among groups, suggesting that Cav3.1 2/2 -associated adverse remodelling was not associated with changes in cardiac hypertrophic responses.
Potential limitations
Although this study revealed deleterious effects of Cav3.1 but not Cav3.2 knockout on post-MI ventricular remodelling, we did not establish the mechanistic basis of these interesting findings. The most likely explanation is that increased Cav3.1-channel function is part of the adaptive response to the contractile impairment caused by loss of myocardial tissue due to infarction. Jaleel et al. 16 have
shown that enhanced Cav3.1 expression increases myocardial contractility without causing negative remodelling effects, unlike enhanced L-type Cav1.2-subunit expression. Increased T-type current has been demonstrated to be part of the hypertrophic response of the heart. 4 We did not observe up-regulation of Cav3.1 or Cav3.2 mRNA post-MI, and so if I CaT was up-regulated post-MI, translational, or posttranslational mechanisms would have to be involved. We attempted to assess Cav3.1 and Cav3.2 protein expression by western blot, but were unable to do so because of the non-specificity of available antibodies and weak signals at the expected molecular masses. Further evaluation of the adaptive role of Cav3.1-subunits in post-MI remodelling and of the underlying mechanisms would clearly be of interest. This work was performed in a rodent model and extrapolation to other species, particularly man, should be cautious. LA, Cav3.2 2/2 LV, and 10, 10, 6, 6 samples for the corresponding groups post-MI. *P , 0.05, **P , 0.01, ***P , 0.001, ANOVA with Tukey post-tests.
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